Bulletin from Extraordinary General Meeting in Karessa Pharma Holding AB (publ) on the 3rd of March 2017
At the Extraordinary General Meeting of Karessa Pharma Holding AB (publ) on March 3rd 2017, Ulf Lindberg was elected to the Board of Directors as new Chairman of the Board and Michael Brobjer was elected as new Board member. Michael Brobjer also takes over as CEO.
Ulf Lindberg
Ulf Lindberg (born 1952) has more than 15 years’ experience from the pharmaceutical industry. For 7 years he was responsible for sales and marketing roles at the American company Lederle, and also for clinical research. Thereafter, Pharmacia for 8 years as Head of Marketing in Scandinavia, Director Business Area Allergy globally and later member of the executive committee as Head of communication. Later Ulf founded Eductus/Competencia, which had a turnover of approximately SEK 250 million in year 3, and then Sweden's largest commercial education company. After that, Ulf was CEO for Pricer in the USA for 4 years. Today he is CEO at Enhancer and works as advisor to companies and organizations on request of owners, boards and top management.
Michael Brobjer
Michael Brobjer (born 1960) has an MSc in Chemical Engineering. Michael has 30 years of experience from drug development, project management and management positions in marketing, sales and business development at pharmaceutical companies. Most recently he worked at APL, where he has successfully been Director of Marketing & Business Area Life science for 8 years with responsibility for business development. APL develops and manufactures pharmaceuticals to companies worldwide and have a turnover of SEK 1.2 billion. Previously, Michael has also worked at Biovitrum, Pharmacia&Upjohn and KabiPharmacia.
After today’s General Meeting, the Board of Karessa Pharma Holding consists of Ulf Lindberg (Chairman), Scott Boyer, Stefan Arver and Michael Brobjer.
Michael Brobjer has also succeeded Torbjörn Kemper as CEO today.
This information is such information that Karessa Pharma Holding AB (publ) is obliged to disclose public according to the European Union's Market Abuse Regulation. The information was provided by the contact person above for publication on 3 March 2017, 16.55 CET.
FOR MORE INFORMATION, PLEASE CONTACT:
Michael Brobjer, CEO, Karessa Pharma Holding AB (publ)
Tel: +46 8-768 22 33
Email: michael.brobjer@karessa.se
About Karessa Pharma Holding AB
Karessa's unique technology allows pharmaceuticals to take a shortcut to the right place in the body. Karessa develops new pharmaceuticals based on proven pharmaceutical substances in order to offer men with impotence problems a fast and more reliable effect. Two pivotal-based clinical trials with Karessa's most advanced projects, based on the active substance in Viagra, are expected to be initiated during 2017. Karessa is listed on Nasdaq First North and has Remium as Certified Advisor. For more information, please visit karessa.se
Tags: